{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:14:01Z","timestamp":1793996041588,"version":"4.8.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s43440-022-00390-z","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T13:18:51Z","timestamp":1658927931000},"page":"557-569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["GSK-3\u03b2-mediated regulation of Nrf2\/HO-1 signaling as a new therapeutic approach in the treatment of movement disorders"],"prefix":"10.1007","volume":"74","author":[{"given":"Divya","family":"Soni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7978-1043","authenticated-orcid":false,"given":"Puneet","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"issue":"7","key":"390_CR1","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/nan.12757","volume":"47","author":"M Murthy","year":"2021","unstructured":"Murthy M, Cheng YY, Holton JL, Bettencourt C. Neurodegenerative movement disorders: an epigenetics perspective and promise for the future. Neuropathol Appl Neurobiol. 2021;47(7):897\u2013909.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"16","key":"390_CR2","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.3390\/molecules24162939","volume":"24","author":"X Huang","year":"2019","unstructured":"Huang X, Li N, Pu Y, Zhang T, Wang B. Neuroprotective effects of ginseng phytochemicals: recent perspectives. Molecules. 2019;24(16):2939.","journal-title":"Molecules"},{"key":"390_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/978-3-030-86495-8_16","volume-title":"Functional movement disorder in older adults, in functional movement disorder","author":"M Moscovich","year":"2022","unstructured":"Moscovich M, LaFaver K, Maetzler W. Functional movement disorder in older adults, in functional movement disorder. Berlin: Springer; 2022. p. 197\u2013203."},{"issue":"4","key":"390_CR4","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s11571-020-09653-y","volume":"15","author":"EM Navarro-Lopez","year":"2021","unstructured":"Navarro-Lopez EM, \u00c7elikok U, \u015eeng\u00f6r NS. A dynamical model for the basal ganglia-thalamo-cortical oscillatory activity and its implications in Parkinson\u2019s disease. Cogn Neurodyn. 2021;15(4):693\u2013720.","journal-title":"Cogn Neurodyn"},{"issue":"10","key":"390_CR5","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1523\/JNEUROSCI.0782-21.2022","volume":"42","author":"JW Callahan","year":"2022","unstructured":"Callahan JW, Wokosin DL, Bevan MD. Dysregulation of the basal Ganglia indirect pathway in early symptomatic q175 Huntington\u2019s disease mice. J Neurosci. 2022;42(10):2080\u2013102.","journal-title":"J Neurosci"},{"issue":"2","key":"390_CR6","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/med.21714","volume":"41","author":"C Bento-Pereira","year":"2021","unstructured":"Bento-Pereira C, Dinkova-Kostova AT. Activation of transcription factor Nrf2 to counteract mitochondrial dysfunction in Parkinson\u2019s disease. Med Res Rev. 2021;41(2):785\u2013802.","journal-title":"Med Res Rev"},{"issue":"9","key":"390_CR7","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1016\/j.ymthe.2021.04.035","volume":"29","author":"K Albert","year":"2021","unstructured":"Albert K, Raymundo DP, Panhelainen A, Eesmaa A, Shvachiy L, Ara\u00fajo GR, et al. Cerebral dopamine neurotrophic factor reduces \u03b1-synuclein aggregation and propagation and alleviates behavioral alterations in vivo. Mol Ther. 2021;29(9):2821\u201340.","journal-title":"Mol Ther"},{"key":"390_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2021.105014","volume":"145","author":"S Jayaram","year":"2021","unstructured":"Jayaram S, Krishnamurthy PT. Role of microgliosis, oxidative stress and associated neuroinflammation in the pathogenesis of parkinson\u2019s disease: the therapeutic role of Nrf2 activators. Neurochem Int. 2021;145: 105014.","journal-title":"Neurochem Int"},{"issue":"4","key":"390_CR9","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1007\/s12035-020-02201-z","volume":"58","author":"E Angelopoulou","year":"2021","unstructured":"Angelopoulou E, Paudel YN, Julian T, Shaikh MF, Piperi C. Pivotal role of Fyn kinase in Parkinson\u2019s disease and levodopa-induced dyskinesia: a novel therapeutic target? Mol Neurobiol. 2021;58(4):1372\u201391.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"390_CR10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s40120-021-00309-5","volume":"11","author":"DO Claassen","year":"2022","unstructured":"Claassen DO, Ayyagari R, Garcia-Horton V, Zhang S, Alexander J, Leo S. Real-world adherence to tetrabenazine or deutetrabenazine among patients with huntington\u2019s disease: a retrospective database analysis. Neurology and Therapy. 2022;11(1):435\u201348.","journal-title":"Neurology and Therapy"},{"issue":"1","key":"390_CR11","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/ijerph19010364","volume":"19","author":"P Sivanandy","year":"2022","unstructured":"Sivanandy P, Leey TC, Xiang TC, Ling TC, Wey Han SA, Semilan SLA, et al. Systemic review on parkinson\u2019s disease medications, emphasizing on three recently approved drugs to control Parkinson\u2019s symptoms. Int J Environ Res Public Health. 2022;19(1):364.","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"390_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s11064-020-03186-w","volume":"46","author":"B Avc\u0131","year":"2021","unstructured":"Avc\u0131 B, G\u00fcnayd\u0131n C, G\u00fcven\u00e7 T, Yavuz CK, Kuruca N, Bilge SS. Idebenone ameliorates rotenone-induced Parkinson\u2019s disease in rats through decreasing lipid peroxidation. Neurochem Res. 2021;46(3):513\u201322.","journal-title":"Neurochem Res"},{"issue":"10","key":"390_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","volume":"16","author":"SJ Tabrizi","year":"2020","unstructured":"Tabrizi SJ, Flower MD, Ross CA, Wild EJ. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol. 2020;16(10):529\u201346.","journal-title":"Nat Rev Neurol"},{"key":"390_CR14","first-page":"2","volume":"2","author":"K-F Hua","year":"2021","unstructured":"Hua K-F, Chao A-C, Lin T-Y, Chen W-T, Lee Y-C, Hsu W-H, et al. Ginsenoside compound K reduces the progression of Huntington\u2019s disease via the inhibition of oxidative stress and overactivation of the Atm\/Ampk pathway. J Ginseng Res. 2021;2:2.","journal-title":"J Ginseng Res"},{"issue":"5","key":"390_CR15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000516767","volume":"55","author":"V Crowell","year":"2021","unstructured":"Crowell V, Houghton R, Tomar A, Fernandes T, Squitieri F. Modeling manifest Huntington\u2019s disease prevalence using diagnosed incidence and survival time. Neuroepidemiology. 2021;55(5):361\u20138.","journal-title":"Neuroepidemiology"},{"issue":"2","key":"390_CR16","doi-asserted-by":"publisher","first-page":"780","DOI":"10.3390\/ijms23020780","volume":"23","author":"S Maity","year":"2022","unstructured":"Maity S, Komal P, Kumar V, Saxena A, Tungekar A, Chandrasekar V. Impact of Er stress and Er-mitochondrial crosstalk in Huntington\u2019s disease. Int J Mol Sci. 2022;23(2):780.","journal-title":"Int J Mol Sci"},{"key":"390_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.56808\/3027-7922.2466","volume":"45","author":"S Deepa","year":"2021","unstructured":"Deepa S, Rymbai E, Praveen T, Saravanan J. Neuroprotective effects of farnesol on motor and cognitive impairment against 3-nitropropionic acid-induced Huntington\u2019s disease. Thai J Pharm Sci. 2021;45:1.","journal-title":"Thai J Pharm Sci"},{"key":"390_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.freeradbiomed.2020.11.031","volume":"163","author":"L Naia","year":"2021","unstructured":"Naia L, Carmo C, Campesan S, Fao L, Cotton VE, Valero J, et al. Mitochondrial Sirt3 confers neuroprotection in Huntington\u2019s disease by regulation of oxidative challenges and mitochondrial dynamics. Free Radical Biol Med. 2021;163:163\u201379.","journal-title":"Free Radical Biol Med"},{"issue":"10","key":"390_CR19","doi-asserted-by":"publisher","first-page":"7194","DOI":"10.4049\/jimmunol.181.10.7194","volume":"181","author":"X Hu","year":"2008","unstructured":"Hu X, Zhang D, Pang H, Caudle WM, Li Y, Gao H, et al. Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the Mptp model of Parkinson\u2019s disease. J Immunol. 2008;181(10):7194\u2013204.","journal-title":"J Immunol"},{"key":"390_CR20","first-page":"1","volume-title":"Current psychological approaches in neurodegenerative diseases, in handbook of computational neurodegeneration","author":"P Kormas","year":"2022","unstructured":"Kormas P, Moutzouri A. Current psychological approaches in neurodegenerative diseases, in handbook of computational neurodegeneration. Berlin: Springer; 2022. p. 1\u201329."},{"key":"390_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.freeradbiomed.2015.04.036","volume":"88","author":"AT Dinkova-Kostova","year":"2015","unstructured":"Dinkova-Kostova AT, Abramov AY. The emerging role of Nrf2 in mitochondrial function. Free Radical Biol Med. 2015;88:179\u201388.","journal-title":"Free Radical Biol Med"},{"key":"390_CR22","first-page":"2","volume":"2","author":"X-H Zeng","year":"2014","unstructured":"Zeng X-H, Li Q-Q, Xu Q, Li F, Liu C-Z. Acupuncture mechanism and redox equilibrium. Evid-Based Complement Alternat Med. 2014;2:2.","journal-title":"Evid-Based Complement Alternat Med"},{"key":"390_CR23","first-page":"2","volume":"2","author":"T-I Huang","year":"2021","unstructured":"Huang T-I, Hsieh C-L. Effects of acupuncture on oxidative stress amelioration via Nrf2\/are-related pathways in Alzheimer and Parkinson diseases. Evid-Based Complement Alternat Med. 2021;2:2.","journal-title":"Evid-Based Complement Alternat Med"},{"key":"390_CR24","first-page":"2","volume":"2","author":"J Zhu","year":"2021","unstructured":"Zhu J, Xu X, Liang Y, Zhu R. Downregulation of microrna-15b-5p targeting the Akt3-mediated Gsk-3\u03b2\/\u0392-catenin signaling pathway inhibits cell apoptosis in Parkinson\u2019s disease. BioMed Res Int. 2021;2:2.","journal-title":"BioMed Res Int"},{"key":"390_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-3-030-27480-1_3","volume":"2","author":"BA Pederson","year":"2019","unstructured":"Pederson BA. Structure and regulation of glycogen synthase in the brain. Brain Glycogen Metab. 2019;2:83\u2013123.","journal-title":"Brain Glycogen Metab"},{"key":"390_CR26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/bs.ctdb.2016.11.011","volume":"123","author":"P Patel","year":"2017","unstructured":"Patel P, Woodgett JR. Glycogen synthase kinase 3: a kinase for all pathways? Curr Top Dev Biol. 2017;123:277\u2013302.","journal-title":"Curr Top Dev Biol"},{"key":"390_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3389\/fnmol.2020.00081","volume":"13","author":"J Li","year":"2020","unstructured":"Li J, Ma S, Chen J, Hu K, Li Y, Zhang Z, et al. Gsk-3\u03b2 contributes to parkinsonian dopaminergic neuron death: evidence from conditional knockout mice and tideglusib. Front Mol Neurosci. 2020;13:81.","journal-title":"Front Mol Neurosci"},{"issue":"11","key":"390_CR28","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1161\/CIRCRESAHA.109.197996","volume":"104","author":"M Juhaszova","year":"2009","unstructured":"Juhaszova M, Zorov DB, Yaniv Y, Nuss HB, Wang S, Sollott SJ. Role of glycogen synthase kinase-3\u03b2 in cardioprotection. Circ Res. 2009;104(11):1240\u201352.","journal-title":"Circ Res"},{"key":"390_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnmol.2012.00001","volume":"5","author":"AJ Valvezan","year":"2012","unstructured":"Valvezan AJ, Klein PS. Gsk-3 and Wnt signaling in neurogenesis and bipolar disorder. Front Mol Neurosci. 2012;5:1.","journal-title":"Front Mol Neurosci"},{"key":"390_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.phrs.2015.03.010","volume":"97","author":"M Golpich","year":"2015","unstructured":"Golpich M, Amini E, Hemmati F, Ibrahim NM, Rahmani B, Mohamed Z, et al. Glycogen synthase kinase-3 beta (Gsk-3\u03b2) signaling: implications for Parkinson\u2019s disease. Pharmacol Res. 2015;97:16\u201326.","journal-title":"Pharmacol Res"},{"issue":"11","key":"390_CR31","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/13543776.2020.1815706","volume":"30","author":"C Roca","year":"2020","unstructured":"Roca C, Campillo NE. Glycogen synthase kinase 3 (Gsk-3) inhibitors: a patent update (2016\u20132019). Expert Opin Ther Pat. 2020;30(11):863\u201372.","journal-title":"Expert Opin Ther Pat"},{"key":"390_CR32","doi-asserted-by":"publisher","first-page":"106099","DOI":"10.1016\/j.phrs.2022.106099","volume":"2","author":"SN Zarneshan","year":"2022","unstructured":"Zarneshan SN, Fakhri S, Khan H. Targeting Akt\/Creb\/Bdnf signaling pathway by ginsenosides in neurodegenerative diseases: a mechanistic approach. Pharmacol Res. 2022;2:106099.","journal-title":"Pharmacol Res"},{"key":"390_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174112","volume":"903","author":"N Sharma","year":"2021","unstructured":"Sharma N, Khurana N, Muthuraman A, Utreja P. Pharmacological evaluation of vanillic acid in rotenone-induced Parkinson\u2019s disease rat model. Eur J Pharmacol. 2021;903: 174112.","journal-title":"Eur J Pharmacol"},{"key":"390_CR34","first-page":"2","volume":"2","author":"L Buyan-Dent","year":"2018","unstructured":"Buyan-Dent L, Mangin T, Shannon KM. Pharmaceutical treatment of Parkinson\u2019s disease. Pract Neurol. 2018;2:2.","journal-title":"Pract Neurol"},{"key":"390_CR35","doi-asserted-by":"publisher","first-page":"175628641988860","DOI":"10.1177\/1756286419888601","volume":"12","author":"F Morgante","year":"2019","unstructured":"Morgante F, Bavikatte G, Anwar F, Mohamed B. The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxina (Xeomin\u00ae). Ther Adv Neurol Disord. 2019;12:1756286419888601.","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"390_CR36","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.stemcr.2020.04.011","volume":"14","author":"A Yamaguchi","year":"2020","unstructured":"Yamaguchi A, Ishikawa K-i, Inoshita T, Shiba-Fukushima K, Saiki S, Hatano T, et al. Identifying therapeutic agents for amelioration of mitochondrial clearance disorder in neurons of familial Parkinson disease. Stem Cell Rep. 2020;14(6):1060\u201375.","journal-title":"Stem Cell Rep"},{"key":"390_CR37","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3389\/fphar.2021.648636","volume":"12","author":"H-Z Long","year":"2021","unstructured":"Long H-Z, Cheng Y, Zhou Z-W, Luo H-Y, Wen D-D, Gao L-C. Pi3k\/Akt signal pathway: a target of natural products in the prevention and treatment of Alzheimer\u2019s disease and Parkinson\u2019s disease. Front Pharmacol. 2021;12:619.","journal-title":"Front Pharmacol"},{"issue":"4","key":"390_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152931","volume":"11","author":"L Zhang","year":"2016","unstructured":"Zhang L, Cen L, Qu S, Wei L, Mo M, Feng J, et al. Enhancing beta-catenin activity via Gsk3beta inhibition protects Pc12 cells against rotenone toxicity through Nurr1 induction. PLoS ONE. 2016;11(4): e0152931.","journal-title":"PLoS ONE"},{"issue":"8","key":"390_CR39","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.neuropharm.2007.03.017","volume":"52","author":"W Wang","year":"2007","unstructured":"Wang W, Yang Y, Ying C, Li W, Ruan H, Zhu X, et al. Inhibition of glycogen synthase kinase-3\u03b2 protects dopaminergic neurons from Mptp toxicity. Neuropharmacology. 2007;52(8):1678\u201384.","journal-title":"Neuropharmacology"},{"issue":"2","key":"390_CR40","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1021\/cn300182g","volume":"4","author":"JA Morales-Garc\u00eda","year":"2013","unstructured":"Morales-Garc\u00eda JA, Sus\u00edn C, Alonso-Gil S, P\u00e9rez DI, Palomo V, P\u00e9rez C, et al. Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. ACS Chem Neurosci. 2013;4(2):350\u201360.","journal-title":"ACS Chem Neurosci"},{"issue":"10","key":"390_CR41","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1096\/fj.04-1551fje","volume":"18","author":"G Chen","year":"2004","unstructured":"Chen G, Bower KA, Ma C, Fang S, Thiele CJ, Luo J. Glycogen synthase kinase 3\u03b2 (Gsk3\u03b2) mediates 6-hydroxydopamine-induced neuronal death. FASEB J. 2004;18(10):1162\u20134.","journal-title":"FASEB J"},{"issue":"3","key":"390_CR42","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1517\/13543780802716501","volume":"13","author":"A Cuadrado","year":"2009","unstructured":"Cuadrado A, Moreno-Murciano P, Pedraza-Chaverri J. The transcription factor Nrf2 as a new therapeutic target in Parkinson\u2019s disease. Expert Opin Ther Targets. 2009;13(3):319\u201329.","journal-title":"Expert Opin Ther Targets"},{"issue":"3","key":"390_CR43","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1089\/ars.2008.2241","volume":"11","author":"J Clark","year":"2009","unstructured":"Clark J, Simon DK. Transcribe to survive: transcriptional control of antioxidant defense programs for neuroprotection in Parkinson\u2019s disease. Antioxid Redox Signal. 2009;11(3):509\u201328.","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"390_CR44","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/jnr.22184","volume":"88","author":"A Valencia","year":"2010","unstructured":"Valencia A, Reeves PB, Sapp E, Li X, Alexander J, Kegel KB, et al. Mutant huntingtin and glycogen synthase kinase 3-\u0392 accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington\u2019s disease. J Neurosci Res. 2010;88(1):179\u201390.","journal-title":"J Neurosci Res"},{"issue":"37","key":"390_CR45","doi-asserted-by":"publisher","first-page":"33791","DOI":"10.1074\/jbc.M204861200","volume":"277","author":"J Carmichael","year":"2002","unstructured":"Carmichael J, Sugars KL, Bao YP, Rubinsztein DC. Glycogen synthase kinase-3\u03b2 inhibitors prevent cellular polyglutamine toxicity caused by the huntington\u2019s disease mutation. J Biol Chem. 2002;277(37):33791\u20138.","journal-title":"J Biol Chem"},{"key":"390_CR46","first-page":"14","volume":"2","author":"SMA Ruiz","year":"2021","unstructured":"Ruiz SMA, Eldar-Finkelman H. Glycogen synthase kinase-3 inhibitors: preclinical and clinical focus on Cns-a decade onward. Front Mol Neurosci. 2021;2:14.","journal-title":"Front Mol Neurosci"},{"issue":"4","key":"390_CR47","doi-asserted-by":"publisher","first-page":"e2206","DOI":"10.1038\/cddis.2016.104","volume":"7","author":"F L'episcopo","year":"2016","unstructured":"L\u2019episcopo F, Drouin-Ouellet J, Tirolo C, Pulvirenti A, Giugno R, Testa N, et al. Gsk-3\u03b2-Induced tau pathology drives hippocampal neuronal cell death in huntington\u2019s disease: involvement of astrocyte-neuron interactions. Cell Death Dis. 2016;7(4):e2206\u2013e2206.","journal-title":"Cell Death Dis"},{"issue":"17","key":"390_CR48","doi-asserted-by":"publisher","first-page":"5040","DOI":"10.1093\/hmg\/ddv224","volume":"24","author":"M Fern\u00e1ndez-Nogales","year":"2015","unstructured":"Fern\u00e1ndez-Nogales M, Hern\u00e1ndez F, Miguez A, Alberch J, Gin\u00e9s S, P\u00e9rez-Navarro E, et al. Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington\u2019s disease. Hum Mol Genet. 2015;24(17):5040\u201352.","journal-title":"Hum Mol Genet"},{"key":"390_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2021.105336","volume":"154","author":"I Rippin","year":"2021","unstructured":"Rippin I, Bonder K, Joseph S, Sarsor A, Vaks L, Eldar-Finkelman H. Inhibition of Gsk-3 ameliorates the pathogenesis of Huntington\u2019s disease. Neurobiol Dis. 2021;154: 105336.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"390_CR50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.17305\/bjbms.2012.2525","volume":"12","author":"A Milutinovi\u0107","year":"2012","unstructured":"Milutinovi\u0107 A, Zorc-Pleskovi\u010d R. Glycogen accumulation in cardiomyocytes and cardiotoxic effects after 3npa treatment. Bosn J Basic Med Sci. 2012;12(1):15.","journal-title":"Bosn J Basic Med Sci"},{"key":"390_CR51","first-page":"2","volume":"2","author":"A-G Wu","year":"2022","unstructured":"Wu A-G, Yong Y-Y, Pan Y-R, Zhang L, Wu J-M, Zhang Y, et al. Targeting Nrf2-mediated oxidative stress response in traumatic brain injury: therapeutic perspectives of phytochemicals. Oxid Med Cell Longev. 2022;2:2.","journal-title":"Oxid Med Cell Longev"},{"key":"390_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.113103","volume":"212","author":"JW Choi","year":"2021","unstructured":"Choi JW, Kim S, Yoo JS, Kim HJ, Kim HJ, Kim BE, et al. Development and optimization of halogenated vinyl sulfones as Nrf2 activators for the treatment of Parkinson\u2019s disease. Eur J Med Chem. 2021;212: 113103.","journal-title":"Eur J Med Chem"},{"issue":"7","key":"390_CR53","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3390\/antiox9070630","volume":"9","author":"SA Scuderi","year":"2020","unstructured":"Scuderi SA, Ardizzone A, Paterniti I, Esposito E, Campolo M. Antioxidant and anti-inflammatory effect of Nrf2 inducer dimethyl fumarate in neurodegenerative diseases. Antioxidants. 2020;9(7):630.","journal-title":"Antioxidants"},{"key":"390_CR54","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3389\/fncel.2014.00298","volume":"8","author":"P Ayuso","year":"2014","unstructured":"Ayuso P, Mart\u00ednez C, Pastor P, Lorenzo-Betancor O, Luengo A, Jim\u00e9nez-Jim\u00e9nez FJ, et al. An association study between heme oxygenase-1 genetic variants and Parkinson\u2019s disease. Front Cell Neurosci. 2014;8:298.","journal-title":"Front Cell Neurosci"},{"issue":"8","key":"390_CR55","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.3390\/ijms19082260","volume":"19","author":"M Nitti","year":"2018","unstructured":"Nitti M, Piras S, Brondolo L, Marinari UM, Pronzato MA, Furfaro AL. Heme oxygenase 1 in the nervous system: does it favor neuronal cell survival or induce neurodegeneration? Int J Mol Sci. 2018;19(8):2260.","journal-title":"Int J Mol Sci"},{"key":"390_CR56","doi-asserted-by":"crossref","unstructured":"Kumar H, Koppula S, Kim I-S, Vasant More S, Kim B-W, Choi D-K. Nuclear Factor erythroid 2-related factor 2 signaling in parkinson disease: a promising multi therapeutic target against oxidative stress, neuroinflammation and cell death. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders). 2012; 11(8): 1015\u20131029.","DOI":"10.2174\/1871527311211080012"},{"key":"390_CR57","unstructured":"Alonso-Navarro H, Jim\u00e9nez-Jim\u00e9nez F, Pilo de la Fuente B, and Plaza-Nieto J. Mecanismos Patog\u00e9nicos De La Enfermedad De Parkinson. Tratado de los Trastornos del Movimiento. 2nd edition (ISBN 978\u201384\u201385424\u201376\u20134). 2008: 425\u2013485."},{"issue":"10","key":"390_CR58","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1212\/01.WNL.0000144276.29988.C3","volume":"63","author":"H Hochstrasser","year":"2004","unstructured":"Hochstrasser H, Bauer P, Walter U, Behnke S, Spiegel J, Csoti I, et al. Ceruloplasmin gene variations and substantia nigra hyperechogenicity in parkinson disease. Neurology. 2004;63(10):1912\u20137.","journal-title":"Neurology"},{"issue":"3","key":"390_CR59","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/BF01244786","volume":"74","author":"E Sofic","year":"1988","unstructured":"Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds G, Hebenstreit G, et al. Increased iron (Iii) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm. 1988;74(3):199\u2013205.","journal-title":"J Neural Transm"},{"key":"390_CR60","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/antiox10010061","volume":"10","author":"P Urrutia","year":"2021","unstructured":"Urrutia P, B\u00f3rquez D, N\u00fa\u00f1ez M. Inflaming the brain with iron. Antioxidants. 2021;10:61.","journal-title":"Antioxidants"},{"key":"390_CR61","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.freeradbiomed.2013.01.017","volume":"62","author":"O Weinreb","year":"2013","unstructured":"Weinreb O, Mandel S, Youdim MB, Amit T. Targeting dysregulation of brain iron homeostasis in parkinson\u2019s disease by iron chelators. Free Radical Biol Med. 2013;62:52\u201364.","journal-title":"Free Radical Biol Med"},{"key":"390_CR62","first-page":"19","volume":"2","author":"J Va\u0161kov\u00e1","year":"2012","unstructured":"Va\u0161kov\u00e1 J, Va\u0161ko L, Kron I. Oxidative processes and antioxidative metaloenzymes. Antioxid Enzyme. 2012;2:19\u201358.","journal-title":"Antioxid Enzyme"},{"key":"390_CR63","first-page":"69","volume-title":"The environmental contribution to redox dyshomeostasis in parkinson\u2019s disease, in parkinsonism and the environment","author":"C Garza-Lomb\u00f3","year":"2022","unstructured":"Garza-Lomb\u00f3 C, Franco R. The environmental contribution to redox dyshomeostasis in parkinson\u2019s disease, in parkinsonism and the environment. Berlin: Springer; 2022. p. 69\u2013102."},{"key":"390_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2020.108695","volume":"700","author":"H Ito","year":"2021","unstructured":"Ito H, Kurokawa H, Matsui H. Mitochondrial reactive oxygen species and heme, non-heme iron metabolism. Arch Biochem Biophys. 2021;700: 108695.","journal-title":"Arch Biochem Biophys"},{"issue":"6","key":"390_CR65","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.biocel.2013.02.012","volume":"45","author":"Q He","year":"2013","unstructured":"He Q, Song N, Jia F, Xu H, Yu X, Xie J, et al. Role of \u0391-synuclein aggregation and the nuclear factor E2-related factor 2\/Heme oxygenase-1 pathway in iron-induced neurotoxicity. Int J Biochem Cell Biol. 2013;45(6):1019\u201330.","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"390_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-021-01209-3","volume":"9","author":"A Delaidelli","year":"2021","unstructured":"Delaidelli A, Richner M, Jiang L, van der Laan A, Bergholdt Jul Christiansen I, Ferreira N, et al. \u0391-synuclein pathology in parkinson disease activates homeostatic Nrf2 anti-oxidant response. Acta Neuropathol Commun. 2021;9(1):1\u201316.","journal-title":"Acta Neuropathol Commun"},{"key":"390_CR67","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3389\/fnmol.2018.00165","volume":"11","author":"H Tong","year":"2018","unstructured":"Tong H, Zhang X, Meng X, Lu L, Mai D, Qu S. Simvastatin inhibits activation of Nadph oxidase\/P38 Mapk pathway and enhances expression of antioxidant protein in parkinson disease models. Front Mol Neurosci. 2018;11:165.","journal-title":"Front Mol Neurosci"},{"key":"390_CR68","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejphar.2017.02.005","volume":"798","author":"Y Masaki","year":"2017","unstructured":"Masaki Y, Izumi Y, Matsumura A, Akaike A, Kume T. Protective effect of Nrf2\u2013are activator isolated from green perilla leaves on dopaminergic neuronal loss in a parkinson\u2019s disease model. Eur J Pharmacol. 2017;798:26\u201334.","journal-title":"Eur J Pharmacol"},{"key":"390_CR69","first-page":"2","volume":"2","author":"J He","year":"2020","unstructured":"He J, Zhu G, Wang G, Zhang F. Oxidative stress and neuroinflammation potentiate each other to promote progression of dopamine neurodegeneration. Oxid Med Cell Longev. 2020;2:2.","journal-title":"Oxid Med Cell Longev"},{"issue":"6","key":"390_CR70","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1523\/JNEUROSCI.3696-05.2006","volume":"26","author":"K-J Min","year":"2006","unstructured":"Min K-J, Yang M-s, Kim S-U, Jou I, Joe E-H. Astrocytes induce hemeoxygenase-1 expression in microglia: a feasible mechanism for preventing excessive brain inflammation. J Neurosci. 2006;26(6):1880\u20137.","journal-title":"J Neurosci"},{"issue":"5","key":"390_CR71","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/glia.20947","volume":"58","author":"AI Rojo","year":"2010","unstructured":"Rojo AI, Innamorato NG, Mart\u00edn-Moreno AM, De Ceballos ML, Yamamoto M, Cuadrado A. Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson\u2019s disease. Glia. 2010;58(5):588\u201398.","journal-title":"Glia"},{"key":"390_CR72","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.ejphar.2017.11.023","volume":"818","author":"Y Izumi","year":"2018","unstructured":"Izumi Y, Kataoka H, Inose Y, Akaike A, Koyama Y, Kume T. Neuroprotective effect of an Nrf2-are activator identified from a chemical library on dopaminergic neurons. Eur J Pharmacol. 2018;818:470\u20139.","journal-title":"Eur J Pharmacol"},{"key":"390_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.dscb.2021.100019","volume":"3","author":"S Upadhayay","year":"2021","unstructured":"Upadhayay S, Mehan S. Targeting Nrf2\/Ho-1 anti-oxidant signaling pathway in the progression of multiple sclerosis and influences on neurological dysfunctions. Brain Disord. 2021;3: 100019.","journal-title":"Brain Disord"},{"key":"390_CR74","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3389\/fnmol.2018.00329","volume":"11","author":"J Zheng","year":"2018","unstructured":"Zheng J, Winderickx J, Franssens V, Liu B. A mitochondria-associated oxidative stress perspective on Huntington\u2019s disease. Front Mol Neurosci. 2018;11:329.","journal-title":"Front Mol Neurosci"},{"issue":"2","key":"390_CR75","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3390\/biom5020472","volume":"5","author":"A Weidinger","year":"2015","unstructured":"Weidinger A, Kozlov AV. Biological activities of reactive oxygen and nitrogen species: oxidative stress versus signal transduction. Biomolecules. 2015;5(2):472\u201384.","journal-title":"Biomolecules"},{"issue":"7","key":"390_CR76","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.dnarep.2008.03.012","volume":"7","author":"J-L Yang","year":"2008","unstructured":"Yang J-L, Weissman L, Bohr VA, Mattson MP. Mitochondrial DNA damage and repair in neurodegenerative disorders. DNA Repair. 2008;7(7):1110\u201320.","journal-title":"DNA Repair"},{"issue":"7","key":"390_CR77","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.freeradbiomed.2012.06.008","volume":"53","author":"A Siddiqui","year":"2012","unstructured":"Siddiqui A, Rivera-S\u00e1nchez S, Castro MdR, Acevedo-Torres K, Rane A, Torres-Ramos CA, et al. Mitochondrial DNA damage is associated with reduced mitochondrial bioenergetics in Huntington\u2019s disease. Free Radical Biol Med. 2012;53(7):1478\u201388.","journal-title":"Free Radical Biol Med"},{"issue":"3","key":"390_CR78","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/aps.2014.107","volume":"36","author":"Y Gao","year":"2015","unstructured":"Gao Y, Chu S-F, Li J-P, Zhang Z, Yan J-Q, Wen Z-L, et al. Protopanaxtriol protects against 3-nitropropionic acid-induced oxidative stress in a rat model of huntington\u2019s disease. Acta Pharmacol Sin. 2015;36(3):311\u201322.","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"390_CR79","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1073\/pnas.0408487101","volume":"102","author":"MJ Calkins","year":"2005","unstructured":"Calkins MJ, Jakel RJ, Johnson DA, Chan K, Kan YW, Johnson JA. Protection from mitochondrial complex ii inhibition in vitro and in vivo by Nrf2-mediated transcription. Proc Natl Acad Sci. 2005;102(1):244\u20139.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"390_CR80","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1089\/ars.2008.2236","volume":"11","author":"DA Linseman","year":"2009","unstructured":"Linseman DA. Targeting oxidative stress for neuroprotection. Antioxid Redox Signal. 2009;11(3):421\u20134.","journal-title":"Antioxid Redox Signal"},{"key":"390_CR81","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.neuroscience.2012.07.060","volume":"227","author":"K Gopinath","year":"2012","unstructured":"Gopinath K, Sudhandiran G. Naringin modulates oxidative stress and inflammation in 3-nitropropionic acid-induced neurodegeneration through the activation of nuclear factor-erythroid 2-related factor-2 signalling pathway. Neuroscience. 2012;227:134\u201343.","journal-title":"Neuroscience"},{"issue":"11","key":"390_CR82","doi-asserted-by":"publisher","first-page":"5444","DOI":"10.3390\/ijms22115444","volume":"22","author":"OO Gonchar","year":"2021","unstructured":"Gonchar OO, Maznychenko AV, Klyuchko OM, Mankovska IM, Butowska K, Borowik A, et al. C60 fullerene reduces 3-nitropropionic acid-induced oxidative stress disorders and mitochondrial dysfunction in rats by modulation of P53, Bcl-2 and Nrf2 targeted proteins. Int J Mol Sci. 2021;22(11):5444.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"390_CR83","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.freeradbiomed.2004.04.033","volume":"37","author":"T Nguyen","year":"2004","unstructured":"Nguyen T, Yang CS, Pickett CB. The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Free Radical Biol Med. 2004;37(4):433\u201341.","journal-title":"Free Radical Biol Med"},{"issue":"6","key":"390_CR84","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3390\/cells9061464","volume":"9","author":"M Ikram","year":"2020","unstructured":"Ikram M, Ullah R, Khan A, Kim MO. Ongoing research on the role of gintonin in the management of neurodegenerative disorders. Cells. 2020;9(6):1464.","journal-title":"Cells"},{"issue":"1","key":"390_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-022-02382-5","volume":"19","author":"N Liu","year":"2022","unstructured":"Liu N, Bai L, Lu Z, Gu R, Zhao D, Yan F, et al. Trpv4 contributes to Er stress and inflammation: implications for Parkinson\u2019s disease. J Neuroinflammation. 2022;19(1):1\u201315.","journal-title":"J Neuroinflammation"},{"issue":"4","key":"390_CR86","doi-asserted-by":"publisher","first-page":"325","DOI":"10.5607\/en.2015.24.4.325","volume":"24","author":"GH Kim","year":"2015","unstructured":"Kim GH, Kim JE, Rhie SJ, Yoon S. The role of oxidative stress in neurodegenerative diseases. Exp Neurobiol. 2015;24(4):325.","journal-title":"Exp Neurobiol"},{"key":"390_CR87","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.redox.2017.01.006","volume":"11","author":"M Pajares","year":"2017","unstructured":"Pajares M, Cuadrado A, Rojo AI. Modulation of proteostasis by transcription factor Nrf2 and impact in neurodegenerative diseases. Redox Biol. 2017;11:543\u201353.","journal-title":"Redox Biol"},{"issue":"6","key":"390_CR88","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/biom10060904","volume":"10","author":"\u00c1 Cores","year":"2020","unstructured":"Cores \u00c1, Piquero M, Villacampa M, Le\u00f3n R, Men\u00e9ndez JC. Nrf2 regulation processes as a source of potential drug targets against neurodegenerative diseases. Biomolecules. 2020;10(6):904.","journal-title":"Biomolecules"},{"key":"390_CR89","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.freeradbiomed.2015.05.034","volume":"88","author":"P Canning","year":"2015","unstructured":"Canning P, Sorrell FJ, Bullock AN. Structural basis of Keap1 interactions with Nrf2. Free Radical Biol Med. 2015;88:101\u20137.","journal-title":"Free Radical Biol Med"},{"issue":"1","key":"390_CR90","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1471-4159.2007.05124.x","volume":"105","author":"AI Rojo","year":"2008","unstructured":"Rojo AI, Sagarra MR, Cuadrado A. Gsk-3\u03b2 down-regulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress. J Neurochem. 2008;105(1):192\u2013202.","journal-title":"J Neurochem"},{"key":"390_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174202","volume":"907","author":"J Su","year":"2021","unstructured":"Su J, Zhang J, Bao R, Xia C, Zhang Y, Zhu Z, et al. Mitochondrial dysfunction and apoptosis are attenuated through activation of Ampk\/Gsk-3\u03b2\/Pp2a pathway in Parkinson\u2019s disease. Eur J Pharmacol. 2021;907: 174202.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"390_CR92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0001-8","volume":"6","author":"X Chen","year":"2016","unstructured":"Chen X, Liu Y, Zhu J, Lei S, Dong Y, Li L, et al. Gsk-3\u03b2 downregulates Nrf2 in cultured cortical neurons and in a rat model of cerebral ischemia-reperfusion. Sci Rep. 2016;6(1):1\u201316.","journal-title":"Sci Rep"},{"key":"390_CR93","doi-asserted-by":"publisher","first-page":"154124","DOI":"10.1016\/j.phymed.2022.154124","volume":"2","author":"R Han","year":"2022","unstructured":"Han R, Yu Y, Zhao K, Wei J, Hui Y, Gao J-M. Lignans from eucommia ulmoides oliver leaves exhibit neuroprotective effects via activation of the Pi3k\/Akt\/Gsk-3\u03b2\/Nrf2 signalling pathways in H2o2-treated Pc-12 cells. Phytomedicine. 2022;2:154124.","journal-title":"Phytomedicine"},{"issue":"11","key":"390_CR94","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1016\/j.bbagen.2016.07.005","volume":"1860","author":"SP Mittal","year":"2016","unstructured":"Mittal SP, Khole S, Jagadish N, Ghosh D, Gadgil V, Sinkar V, et al. Andrographolide protects liver cells from H2o2 induced cell death by upregulation of Nrf-2\/Ho-1 mediated via adenosine A2a receptor signalling. Biochim Biophys Acta General Subj. 2016;1860(11):2377\u201390.","journal-title":"Biochim Biophys Acta General Subj."},{"key":"390_CR95","first-page":"2","volume":"2","author":"S Habtemariam","year":"2019","unstructured":"Habtemariam S. The Nrf2\/Ho-1 axis as targets for flavanones: neuroprotection by pinocembrin, naringenin, and eriodictyol. Oxid Med Cell Longev. 2019;2:2.","journal-title":"Oxid Med Cell Longev"},{"issue":"7","key":"390_CR96","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/molecules24071377","volume":"24","author":"G Armagan","year":"2019","unstructured":"Armagan G, Sevgili E, G\u00fcrkan FT, K\u00f6se FA, Bilgi\u00e7 T, Dagc\u0131 T, et al. Regulation of the Nrf2 pathway by glycogen synthase kinase-3\u03b2 in Mpp+-induced cell damage. Molecules. 2019;24(7):1377.","journal-title":"Molecules"},{"issue":"21","key":"390_CR97","doi-asserted-by":"publisher","first-page":"14841","DOI":"10.1074\/jbc.M513737200","volume":"281","author":"M Salazar","year":"2006","unstructured":"Salazar M, Rojo AI, Velasco D, de Sagarra RM, Cuadrado A. Glycogen synthase kinase-3\u03b2 inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J Biol Chem. 2006;281(21):14841\u201351.","journal-title":"J Biol Chem"},{"key":"390_CR98","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.toxlet.2017.02.022","volume":"271","author":"X-L Zhang","year":"2017","unstructured":"Zhang X-L, Yuan Y-H, Shao Q-H, Wang Z-Z, Zhu C-G, Shi J-G, et al. Dj-1 regulating Pi3k-Nrf2 signaling plays a significant role in bibenzyl compound 20c-mediated neuroprotection against rotenone-induced oxidative insult. Toxicol Lett. 2017;271:74\u201383.","journal-title":"Toxicol Lett"},{"key":"390_CR99","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.neuroscience.2014.12.018","volume":"287","author":"A Khan","year":"2015","unstructured":"Khan A, Jamwal S, Bijjem K, Prakash A, Kumar P. Neuroprotective effect of hemeoxygenase-1\/glycogen synthase kinase-3\u03b2 modulators in 3-nitropropionic acid-induced neurotoxicity in rats. Neuroscience. 2015;287:66\u201377.","journal-title":"Neuroscience"},{"issue":"5","key":"390_CR100","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/j.1468-1331.2009.02908.x","volume":"17","author":"J Infante","year":"2010","unstructured":"Infante J, Garc\u00eda-Gorostiaga I, S\u00e1nchez-Juan P, Sierra M, Mart\u00edn-Gurpegui J, Terrazas J, et al. Synergistic effect of two oxidative stress-related genes (heme oxygenase-1 and Gsk3\u03b2) on the risk of parkinson\u2019s disease. Eur J Neurol. 2010;17(5):760\u20132.","journal-title":"Eur J Neurol"},{"issue":"4","key":"390_CR101","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1021\/acschemneuro.0c00722","volume":"12","author":"HH Arab","year":"2021","unstructured":"Arab HH, Safar MM, Shahin NN. Targeting ros-dependent Akt\/Gsk-3\u03b2\/Nf-\u039ab and Dj-1\/Nrf2 pathways by dapagliflozin attenuates neuronal injury and motor dysfunction in rotenone-induced parkinson\u2019s disease rat model. ACS Chem Neurosci. 2021;12(4):689\u2013703.","journal-title":"ACS Chem Neurosci"},{"key":"390_CR102","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3389\/fnins.2020.00723","volume":"14","author":"Y Huang","year":"2020","unstructured":"Huang Y, Sun L, Zhu S, Xu L, Liu S, Yuan C, et al. Neuroprotection against Parkinson\u2019s disease through the activation of Akt\/Gsk3\u03b2 signaling pathway by tovophyllin A. Front Neurosci. 2020;14:723.","journal-title":"Front Neurosci"},{"issue":"10","key":"390_CR103","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.3390\/nu10101449","volume":"10","author":"C-R Wu","year":"2018","unstructured":"Wu C-R, Chang H-C, Cheng Y-D, Lan W-C, Yang S-E, Ching H. Aqueous extract of davallia mariesii attenuates 6-hydroxydopamine-induced oxidative damage and apoptosis in B35 cells through inhibition of caspase cascade and activation of Pi3k\/Akt\/Gsk-3\u03b2 pathway. Nutrients. 2018;10(10):1449.","journal-title":"Nutrients"},{"issue":"5","key":"390_CR104","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1007\/s11064-017-2183-2","volume":"42","author":"J Nataraj","year":"2017","unstructured":"Nataraj J, Manivasagam T, Justin Thenmozhi A, Essa MM. Neurotrophic effect of asiatic acid, a triterpene of centella asiatica against chronic 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine hydrochloride\/probenecid mouse model of Parkinson\u2019s disease: the role of Mapk, Pi3k-Akt-Gsk3\u03b2 and Mtor signalling pathways. Neurochem Res. 2017;42(5):1354\u201365.","journal-title":"Neurochem Res"},{"issue":"5","key":"390_CR105","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.neuint.2013.07.003","volume":"63","author":"H-M Wang","year":"2013","unstructured":"Wang H-M, Zhang T, Li Q, Huang J-K, Chen R-F, Sun X-J. Inhibition of glycogen synthase kinase-3\u03b2 by lithium chloride suppresses 6-hydroxydopamine-induced inflammatory response in primary cultured astrocytes. Neurochem Int. 2013;63(5):345\u201353.","journal-title":"Neurochem Int"},{"issue":"9","key":"390_CR106","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1096\/fj.08-120410","volume":"23","author":"T Duka","year":"2009","unstructured":"Duka T, Duka V, Joyce JN, Sidhu A. \u0391-synuclein contributes to Gsk-3\u03b2-catalyzed tau phosphorylation in Parkinson\u2019s disease models. FASEB J. 2009;23(9):2820\u201330.","journal-title":"FASEB J"},{"key":"390_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2020.135268","volume":"736","author":"Y Inose","year":"2020","unstructured":"Inose Y, Izumi Y, Takada-Takatori Y, Akaike A, Koyama Y, Kaneko S, et al. Protective effects of Nrf2\u2013are activator on dopaminergic neuronal loss in parkinson disease model mice: possible involvement of heme oxygenase-1. Neurosci Lett. 2020;736: 135268.","journal-title":"Neurosci Lett"},{"issue":"3","key":"390_CR108","first-page":"1419","volume":"18","author":"S Darabi","year":"2019","unstructured":"Darabi S, Noori-Zadeh A, Abbaszadeh H-A, Rajaei F, Bakhtiyari S. Trehalose neuroprotective effects on the substantia nigra dopaminergic cells by activating autophagy and non-canonical Nrf2 pathways. Iran J Pharmac Res IJPR. 2019;18(3):1419.","journal-title":"Iran J Pharmac Res IJPR"},{"key":"390_CR109","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.expneurol.2017.05.009","volume":"295","author":"S Moreira","year":"2017","unstructured":"Moreira S, Fonseca I, Nunes MJ, Rosa A, Lemos L, Rodrigues E, et al. Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson\u2019s disease. Exp Neurol. 2017;295:77\u201387.","journal-title":"Exp Neurol"},{"issue":"7","key":"390_CR110","doi-asserted-by":"publisher","first-page":"4866","DOI":"10.1007\/s12035-016-0028-7","volume":"54","author":"HE Michel","year":"2017","unstructured":"Michel HE, Tadros MG, Esmat A, Khalifa AE, Abdel-Tawab AM. Tetramethylpyrazine ameliorates rotenone-induced parkinson\u2019s disease in rats: involvement of its anti-inflammatory and anti-apoptotic actions. Mol Neurobiol. 2017;54(7):4866\u201378.","journal-title":"Mol Neurobiol"},{"issue":"2","key":"390_CR111","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3892\/mmr.2015.4657","volume":"13","author":"Q Cui","year":"2016","unstructured":"Cui Q, Li X, Zhu H. Curcumin ameliorates dopaminergic neuronal oxidative damage via activation of the Akt\/Nrf2 pathway. Mol Med Rep. 2016;13(2):1381\u20138.","journal-title":"Mol Med Rep"},{"issue":"7","key":"390_CR112","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011838","volume":"5","author":"NG Innamorato","year":"2010","unstructured":"Innamorato NG, Jazwa A, Rojo AI, Garc\u00eda C, Fern\u00e1ndez-Ruiz J, Grochot-Przeczek A, et al. Different susceptibility to the Parkinson\u2019s toxin mptp in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. PLoS ONE. 2010;5(7): e11838.","journal-title":"PLoS ONE"},{"issue":"16","key":"390_CR113","doi-asserted-by":"publisher","first-page":"13898","DOI":"10.1074\/jbc.M209164200","volume":"278","author":"M Salinas","year":"2003","unstructured":"Salinas M, Diaz R, Abraham NG, de Galarreta CMR, Cuadrado A. Nerve growth factor protects against 6-hydroxydopamine-induced oxidative stress by increasing expression of heme oxygenase-1 in a phosphatidylinositol 3-kinase-dependent manner. J Biol Chem. 2003;278(16):13898\u2013904.","journal-title":"J Biol Chem"},{"key":"390_CR114","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.exger.2017.06.009","volume":"96","author":"A Silva-Palacios","year":"2017","unstructured":"Silva-Palacios A, Ostolga-Chavarr\u00eda M, Buelna-Chontal M, Garibay C, Hern\u00e1ndez-Res\u00e9ndiz S, Rold\u00e1n F, et al. 3-Np-induced Huntington\u2019s-like disease impairs Nrf2 activation without loss of cardiac function in aged rats. Exp Gerontol. 2017;96:89\u201398.","journal-title":"Exp Gerontol"},{"key":"390_CR115","first-page":"2","volume":"2","author":"P Liu","year":"2019","unstructured":"Liu P, Li Y, Yang W, Liu D, Ji X, Chi T, et al. Prevention of Huntington\u2019s disease-like behavioral deficits in R6\/1 mouse by tolfenamic acid is associated with decreases in mutant huntingtin and oxidative stress. Oxid Med Cell Longev. 2019;2:2.","journal-title":"Oxid Med Cell Longev"},{"issue":"24","key":"390_CR116","doi-asserted-by":"publisher","first-page":"22925","DOI":"10.1074\/jbc.M414635200","volume":"280","author":"AY Shih","year":"2005","unstructured":"Shih AY, Imbeault S, Barakauskas V, Erb H, Jiang L, Li P, et al. Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo. J Biol Chem. 2005;280(24):22925\u201336.","journal-title":"J Biol Chem"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-022-00390-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-022-00390-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-022-00390-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:07:45Z","timestamp":1727654865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-022-00390-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":116,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["390"],"URL":"https:\/\/doi.org\/10.1007\/s43440-022-00390-z","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]},"assertion":[{"value":"11 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}